What this trial studies
This prospective study aims to evaluate the effects of menopausal hormone therapy (MHT) on liver function, lipid profiles, and hepatic steatosis in postmenopausal women. A total of 44 participants will be divided into two groups: 22 received MHT and 22 were monitored without treatment. Biochemical parameters, FIB-4 scores, and attenuation imaging (ATI) measurements are assessed at baseline and after six months. The study investigates whether MHT is associated with favorable changes in liver enzymes, hepatic fat accumulation, and noninvasive fibrosis markers.
Conditions in scope
- Menopause
- Non Alcholic Fatty Liver Disease
- Hepatic Steatosis
Interventions
- Menopausal hormone therapy (Drug) — Menopausal hormone therapy including oral or transdermal estrogen, with or without progestin, administered based on clinical indications.
Who can join
Women only · Ages 40 Years and up
Inclusion criteria
- Female participants aged 40 years or older
- Postmenopausal status (defined as ≥12 months of amenorrhea)
- No prior use of menopausal hormone therapy in the last 6 months
- Willingness to participate and provide informed consent
Exclusion criteria
- History of liver disease, liver malignancy, or liver transplantation
- Current or past alcohol consumption exceeding 20g/day
- Premature ovarian failure
- History of any active malignancy
- Use of medications known to affect liver enzymes or fat metabolism
- Current participation in another clinical trial
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Istanbul | Beyoğlu | Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: N/A
- Start date: 2024-10-30
- Primary completion: 2025-09-30
- Last update posted: 2026-01-27
- First posted: 2025-08-05
Sponsor & contact
Lead sponsor: Ipek B. Ozcivit Erkan, MD (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Change in ATI (Attenuation Imaging) value from baseline to 6 months (Baseline and 6 months)
Quantitative measurement of hepatic steatosis using ultrasound-based attenuation imaging (ATI). A decrease in ATI indicates improvement in hepatic fat content.
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07103603 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.